{"page_content": "Zealand \nPharma\u2019s first \nindependent \nlaunch\nWith our established US \ncommercial presence and \nintroduction of Zegalogue to \nsupplement our sales of V-Go to \npatients, Zegalogue became the \nsecond of our five products to be \nlaunched by 2025 in the US.  US organization\nIn line with our strategy of independently commercializ-ing our medicines, Zealand Pharma has established and then further optimized our own fully-fledged commercial operation in the US, preparing us for our future launches expected by 2025.\nOur purchase of the assets of Valeritas Inc. in 2020 pro-\nvided us with the infrastructure to sell our products in the US market. In 2021, we have utilized the benefit of that acquisition and further developed our commercial pres-ence as a fully integrated biotech company with an es-tablished footprint in the US diabetes market by launching Zegalogue. This focus on developing our US commercial platform was a pivotal element in our strategy and ena-bled us to make progress with the launch of Zegalogue in the US. This development will allow us to independently launch and market the future medicines we develop in the US market. 12\nZealand Pharma  \u221e  Annual Report 2021Zealand Pharma\u2019s first independent launch", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 11, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}